Gandotinib

AT9283, AZD4547, AZD6244, BGJ398, crizotinib, pictilisib, ibrutinib, PD173074, ruxolitinib, TAE684, and gandotinib were all purchased from Selleck Chemicals, AUY922, dovitinib, everolimus, gefitinib, mubritinib, saracatinib, sunitinib, and ZSTK474 were from LC Laboratories, CH5424802 was from Active Biochem, SB525334 was from Tocris, and fedratinib was from Axon Medchem. The human gastric cancer cell line SNU-16 was obtained from ATCC and was cultured in RPMI 1640 medium supplemented with 10 % fetal bovine serum according to the manufacturer’s instructions.

Rat pups (PND2) were injected intraperitoneally with rhMIS (3 mg/kg), gandotinib (20 mg/kg, Selleckchem), SP600125 (30 mg/kg, Selleckchem), CYC-116 (50 mg/kg, Selleckchem), or ruxolitinib (20 mg/kg, MedchemExpress) once per day for 10 d. At the end of treatment, necropsy was performed and the ovaries were dissected, fixed, processed, embedded, and H&E-stained for follicle count.

Misr2/Amhr2Cre knock-in mice were purchased from the Mutant Mouse Regional Resource Centers (strain B6, 129S7- Amhr2^{tm3(cre)Bhr/Mmnc}, back-crossed with C57BL/6J). Tail genotyping of the Misr2-cre knock-in and wild-type mice was done with the REDExtract-N-Amp Tissue PCR Kit (Sigma) with the previously described sets of primers (42 (link)). Misr2^cre/cre males had retained Mullerian ducts confirming the loss-of-function of Misr2. Misr2^cre/cre and Misr2^+/cre transgenic female mice (PND3) were injected intraperitoneally with rhMIS (3 mg/kg), gandotinib (20 mg/kg, Selleckchem), SP600125 (30 mg/kg, Selleckchem), CYC-116 (50 mg/kg, Selleckchem), or ruxolitinib (20 mg/kg once per day for 4 d, then killed by decapitation. The ovaries were processed, and follicle counts were performed as described above.